Quantcast

Industry news that matters to you.  Learn more

The Michael J. Fox Foundation Funds Research to Develop Parkinson’s Blood Test

Research being performed by Durin Technologies, Inc., exploring the development of a novel blood test for Parkinson’s disease was recently awarded a second grant from The Michael J. Fox Foundation for Parkinson’s Research.

Personalized Medicine Roadmap: Definiens Releases Five Steps to Utilize Data Mining with Image Analysis

Definiens, a healthcare company that advances personalized medicine through image analysis and digital pathology solutions, recently released tips for integrating data mining with image analysis. As pathologists, researchers and clinicians seek to advance personalized medicine through the development and prescription of targeted therapies, data generated through image analysis of digitized tissue sections is becoming essential to stratifying patients and providing personalized care.

Utility Of Rubicon Genomics’ ThruPLEX-FD Kit Validated In Study Showing “Liquid Biopsy” Can Track Genomic Evolution Of Cancer In Response To Therapy

Rubicon Genomics, Inc., a leader in the development and commercialization of innovative sample-specific nucleic acid library preparation products used in research and clinical testing, recently reported that its ThruPLEXTM-FD Prep Kits contributed to the success of a breakthrough study recently published in Nature1 that showed that genomic data extracted from the plasma of cancer patients can be used to track drug resistance and potentially guide treatment.

Cardiac Biomarker ST2 Proves Far Superior To Galectin-3 In A Head-to-Head Study

Critical Diagnostics recently announced that the study, “Head-to-head comparison of two myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 vs. Galectin-3”, recently published online in JACC (the Journal of the American College of Cardiology) comparing the company’s novel cardiac biomarker ST2 to Galectin-3 (Gal-3), a biomarker from BG Medicine (NASDAQ: BGMD), found ST2 to be superior.

FDA Grants Genentech’s Perjeta Accelerated Approval for Use Before Surgery in People With HER2-Positive Early Stage Breast Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), recently announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval of a Perjeta® (pertuzumab) regimen for neoadjuvant treatment (use before surgery) in people with high-risk, HER2-positive early stage breast cancer. This approval is based primarily on data from a Phase II study showing that nearly 40 percent of people receiving the combination of Perjeta, Herceptin® (trastuzumab) and docetaxel chemotherapy had no evidence of tumor tissue detectable at the time of surgery (known as a pathological complete response, or pCR). The Perjeta regimen is the first neoadjuvant breast cancer treatment approved by the FDA and also the first to be approved based on pCR data.